Department of Pediatrics, University of Alberta, Edmonton, Canada.
BMC Pediatr. 2014 Jun 20;14:158. doi: 10.1186/1471-2431-14-158.
Considerable heterogeneity has been observed in the selection and reporting of disease-specific pediatric outcome measures in randomized controlled trials (RCTs). This makes interpretation of results and comparison across trials challenging. Outcome measures in pediatric anaphylaxis trials have never previously been systematically assessed. This systematic review (SR) identified and assessed outcome measures used in RCTs of anaphylaxis treatment in children. As a secondary objective, this SR assessed the evidence for current treatment modalities for anaphylaxis in the pediatric population.
We searched MEDLINE, EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), and CINAHL from 2001 until December 2012. We also searched websites listing ongoing trials. We included randomized and controlled trials of anaphylaxis treatment in patients 0-18 years of age. Two authors independently assessed articles for inclusion.
No published studies fulfilled the inclusion criteria.
There is an alarming absence of RCTs evaluating the treatments for anaphylaxis in children. High quality studies are needed and are possible to design, despite the severe and acute nature of this condition. Consensus about the selection and validation of appropriate outcome measures will enhance the quality of research and improve the care of children with anaphylaxis.
CRD42012002685.
在随机对照试验（RCT）中，疾病特异性儿科结局测量的选择和报告存在很大的异质性。这使得结果的解释和试验间的比较变得具有挑战性。儿科过敏反应试验的结局测量指标以前从未被系统评估过。本系统评价（SR）确定并评估了儿童过敏反应治疗 RCT 中使用的结局测量指标。作为次要目标，本 SR 评估了当前儿科人群过敏反应治疗方法的证据。
我们从 2001 年到 2012 年 12 月，在 MEDLINE、EMBASE、The Cochrane Library、Cochrane 对照试验中心注册库（CENTRAL）和 CINAHL 上进行了检索。我们还搜索了正在进行试验的网站。我们纳入了 0-18 岁患者过敏反应治疗的随机和对照试验。两名作者独立评估文章是否符合纳入标准。
没有发表的研究符合纳入标准。
令人震惊的是，没有 RCT 评估儿童过敏反应的治疗方法。尽管这种情况严重且急性，但仍需要并有可能设计高质量的研究。关于选择和验证适当的结局测量指标的共识将提高研究质量，并改善过敏反应患儿的护理。
CRD42012002685。
